Poll: ISAR-REACT 5 Trial

The ISAR-REACT 5 (Intracoronary Stenting and Antithrombotic Regimen 5) trial presented at the European Society of Cardiology Congress 2019 showed prasugrel had significantly lower major adverse cardiovascular events compared with ticagrelor in patients undergoing percutaneous coronary intervention (PCI).

Engage with fellow ACC members by discussing this article and ESC Congress 2019 on ACC's Member Hub message board. Please log into ACC.org to participate. Not a member? Join the ACC today!

Clinical Topics: Acute Coronary Syndromes, Anticoagulation Management, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Anticoagulation Management and ACS, Interventions and ACS, Interventions and Imaging, Angiography, Nuclear Imaging

Keywords: Acute Coronary Syndrome, Anticoagulants, Coronary Angiography, Angiography, Percutaneous Coronary Intervention, Stents, ESC 19, ESC Congress

< Back to Listings